目的：系统评价奥洛他定联合普拉洛芬治疗过敏性结膜炎的疗效和安全性。

方法：以“奥洛他定滴眼液”“普拉洛芬滴眼液”“过敏性结膜炎”为关键词，检索Embase、Cochrane library、Pubmed、中国知网数据库、万方数据库、维普中文科技期刊数据库中奥洛他定联合普拉洛芬治疗过敏性结膜炎的临床对照试验，检索时间为建库至2022-01-01； 采用Cochrane偏倚风险评估工具对纳入研究进行质量评估，对纳入文献的发表偏倚进行Egger检验，使用RevMan 5.3统计软件进行Meta分析。

结果：纳入符合条件的文献共24篇，全部为中文文献，合计患者2 443例2 547眼，试验组给予奥洛他定联合普拉洛芬治疗，对照组采用奥洛他定单药治疗。试验组的临床有效率优于对照组(OR=4.42，95%CI：3.37～5.80，P<0.00001)； 试验组的不良反应发生率和对照组无显著性差异(OR=0.89，95%CI：0.45～1.75，P=0.73)； 对临床有效率、不良反应发生率进行Egger检验，结果显示临床有效率存在发表偏倚，但通过剪补法分析得知存在的发表偏倚未对结果造成影响。

结论：奥洛他定联合普拉洛芬可提高过敏性结膜炎的临床疗效，今后可开展多中心、随机双盲研究，进而提高证据强度。

METHODS: Using “olopatadine eye drops”, “pranoprofen eye drops” and “allergic conjunctivitis” as keywords, the controlled clinical trials of olopatadine combined with pranoprofen in the treatment of allergic conjunctivitis were searched from Embase, Cochrane library, PubMed, CNKI, Wanfang and VIP database, with an retrieval time from the establishment of the database to January 1, 2022; The Cochrane Risk of Bias Assessment Tool was used to assess the quality of the included studies, and the Egger's test was performed for publication bias of the included literatures. Meta-analysis was performed by using RevMan 5.3.

RESULTS: A total of 24 eligible Chinese literatures were included, with 2 443 patients(2 547 eyes)in total. The test group was administrated olopatadine combined with pranoprofen, and the control group was treated with olopatadine monotherapy; The results of Meta-analysis showed that the clinical efficiency of the test group was better than that of the control group(OR=4.42, 95%CI:3.37-5.80,P<0.00001); There was no significant difference in the incidence of adverse reactions between the test group and the control group(OR=0.89, 95%CI: 0.45-1.75, P=0.73); Egger's test was conducted on the clinical efficiency and the incidence of adverse reactions, which showed that there was publication bias in the clinical efficiency, but the existed publication bias did not affected results through trim and fill method.

CONCLUSIONS: The combination of olopatadine with pranoprofen may improve the clinical efficacy of allergic conjunctivitis. In the future, multicentered, randomized, double-blind studies can be conducted to improve the strength of the evidence.